Mylan completed its acquisition of Meda on August 5, 2016. Learn more.
Meda is a leading international specialty pharma company with a broad product portfolio reaching more than 80% of the global pharmaceutical market. Sales at the end of 2014 amounted to more than SEK 15 billion (pro forma SEK 18.7 billion). Meda is thereby the 48th largest pharmaceutical company in the world.
At the end of 2014 Meda had 5,202 (3,326) employees, 2,996 (2,009) of which worked in sales and marketing. The company’s main focus is sales and marketing and Meda has its own sales organizations in more than 60 countries. Sales and marketing activities are carried out via distributors in countries where Meda has no representation and globally Meda’s products are sold in more than 150 countries. Over the past few years Meda’s presence in growth markets has grown. The marketing organizations in these markets employ about 1,083 people (720).
In 2014 Meda acquired the Italian specialty pharma company Rottapharm and after the acquisition, around 60% of Meda’s product sales are in the prescription area (Rx) and around 40% are in non-prescription (Cx and OTC). Meda has a broad product portfolio but there are three key therapy areas – Respiratory, Dermatology and Pain and Inflammation – accounting for around 50% of Group sales.
Meda does not conduct any, early-stage pharmaceutical development. New products are secured through acquisitions. Instead, Meda is focused on market-adapted product development in key therapy areas, and sales and marketing.
Rx products are prescription based pharmaceuticals prescribed by doctors and therapists for patients.
OTC products are over the counter products sold directly to consumers via pharmacies and retail chains.
Cx are clinically-proven consumer healthcare products recommended by doctors and pharmacists to consumers.